Keylika
Keylika is developing the world’s first resorbable buccal patch (Rx) for iron administration to treat IDA, especially in women of childbearing age suffering from moderate-to-severe ID, as a potential best-in-class breakthrough therapy.
Headquarters
Keylika
135 Mississippi St
San Francisco
CA 94107
United States
Keylika is developing the world’s first resorbable buccal patch (Rx) for iron administration to treat IDA, especially in women of childbearing age suffering from moderate-to-severe ID, as a potential best-in-class breakthrough therapy. The iron drug is an NCE developed in-house and tailored to the transbuccal route of administration.
Keylika develops small-to-large-molecule drugs and optimised drug delivery technologies to effect the best clinical outcomes across human and animal health. Keylika’s platform lies at the unique intersection of de novo drug design and micro/nanotechnologies (semiconductor-based microsystems, devices and formulations) for non-oral, systemic drug delivery without molecular size constraints to generate best-in-class therapies.
Keylika is an early-stage biotech startup backed by Y Combinator (Summer 2022 batch) and other angel investors.
